Autolus Therapeutics PLC (AUTL)
| Market Cap | 460.23M |
| Revenue (ttm) | 1.62M |
| Net Income (ttm) | -140.18M |
| Shares Out | 52.09M |
| EPS (ttm) | -1.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $8.80 |
| Previous Close | $8.90 |
| Change ($) | -0.10 |
| Change (%) | -1.12% |
| Day's Open | 8.99 |
| Day's Range | 8.70 - 9.12 |
| Day's Volume | 153,342 |
| 52-Week Range | 4.20 - 16.30 |
• Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), with full data from the AUTO1-AL1 study expected in 2022 • Company intends ...
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today anno...
AUTO3 continues to show a differentiated product profile supporting outpatient administration
Updated data from the ALLCAR study suggests AUTO1's potential for transformational activity in adult patients with r/r ALL
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Autolus - a developer of next-generation programmed T cell therapies - has shown continued progress in advancing its anti-cancer pipeline. AUTO1 has entered a pivotal trial for ALL and may ach...
LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today anno...
Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q3 2020 Results - Earnings Call Transcript
LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today anno...
- AUTO3 shows promise of a highly differentiated product profile
LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today a...
Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q2 2020 Results - Earnings Call Transcript
- Conference call to be held on August 6, 2020 at 8:30 am EDT/1:30 pm BST - - Conference call to be held on August 6, 2020 at 8:30 am EDT/1:30 pm BST -
Dr. Jay T. Backstrom appointed to board of directors Dr. Jay T. Backstrom appointed to board of directors
Autolus Therapeutics plc (AUTL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of TRBC2 by a novel CAR T candidate
Is (AUTL) Outperforming Other Medical Stocks This Year?
Pivotal AUTO1 study in adult ALL patients enrolling
As of late, it has definitely been a great time to be an investor in Autolus Therapeutics.
Autolus Therapeutics (AUTL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock ...
As of late, it has definitely been a great time to be an investor Autolus Therapeutics
Autolus Therapeutics Plc (AUTL) CEO Christian Itin on Q1 2020 Results - Earnings Call Transcript
Shares of Autolus Therapeutics (NASDAQ:AUTL) were unchanged at $10.28 after the company reported Q1 results.
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the ...
Autolus Therapeutics (AUTL) CEO Christian Itin on Q4 2019 Results - Earnings Call Transcript
- Initial data show encouraging clinical activity with manageable safety profile - No neurotoxicity observed to date in patients treated with AUTO3 + pembrolizumab
LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today an...
Investors are reacting negatively to the biotech's public stock offering.
LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today an...
LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today an...
Wall Street issued positive recommendation ratings for Autolus Therapeutics plc (NASDAQ:AUTL) and Jianpu Technology Inc (NYSE:JT) even though their stocks plunged over the past year through Tu...
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies
Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T
AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome
As of late, it has definitely been a great time to be an investor in Autolus Therapeutics.
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the t...
Enhancing the anti-tumor potential of CAR T cells for the treatment of solid tumors Enhancing the anti-tumor potential of CAR T cells for the treatment of solid tumors
Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q3 2019 Results - Earnings Call Transcript
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the t...
Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome
LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today an...
Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2019 Results - Earnings Call Transcript
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Autolus Therapeutics PLC. (AUTL) CEO Christian Itin on Q1 2019 Results - Earnings Call Transcript
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
| Industry Biotechnology | IPO Date Jun 22, 2018 |
| CEO Dr. Christian Martin Itin | Employees 290 |
| Stock Exchange NASDAQ | Ticker Symbol AUTL |
Financial Performance
In 2019, AUTL's revenue was $2.91 million, an increase of 106.68% compared to the previous year's $1.41 million. Losses were -$123.85 million, 176.8% more than in 2018.
Analyst Forecasts
According to 10 analysts, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is 20.78, which is an increase of 136.14% from the latest price.